MedTrace Logo

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

NCT01315496 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2013-04-30

No results posted yet for this study

Summary

This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.

Conditions

  • Severe Sepsis
  • Septic Shock

Interventions

DRUG

Immunoglobulin G

Immunoglobulin 1.5-2g/Kg/3days

Sponsors & Collaborators

  • Symyoo

    collaborator INDUSTRY

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Min Ja Kim, Professor · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315496 on ClinicalTrials.gov